DelveInsight's Age-related Macular Degeneration (AMD) - Epidemiology Forecast 2032 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Age-related Macular Degeneration (AMD) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Age-related Macular Degeneration Epidemiology Forecast 2032

DelveInsight&rsquo;s &lsquo;Age-related Macular Degeneration (AMD) - Epidemiology Forecast&ndash;2034&rsquo; report delivers an in-depth understanding of Age-related Macular Degeneration (AMD), historical and forecasted epidemiology as well as trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
<h2>Geographies Covered</h2>
<ul>
<li>The United States</li>
<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)</li>
<li>Japan</li>
</ul>
Study Period: 2021-2034
<h2>Age-related Macular Degeneration (AMD): Disease Understanding</h2>
Age-related Macular Degeneration (AMD) is the leading cause of blindness in elderly patients in developed communities. It is an eye disease of elderly individuals that causes a progressive loss of the central vision needed to drive, read, recognize faces, and see the world in color. AMD's progression leads to loss of central vision, leaving many patients unable to read, write, or recognize both color and detail, thus compromising the quality of life. Although AMD's exact functional pathogenesis is not fully understood, there have been recent improvements in genetic technologies leading to the identification of various polymorphisms that have shown to harbor unique associations with AMD.
&nbsp;
AMD is characterized by progressive degeneration of the macula, the central part of the retina, leading to central vision loss. AMD can be classified as early, intermediate, or late based on its clinical features, including drusen, pigmentation abnormalities, atrophy of the retinal pigment epithelium (RPE), and exudative choroidal neovascularization (CNV).
&nbsp;
AMD can also be characterized as either dry (atrophic or non-neovascular) or wet (exudative or neovascular).
&nbsp;
Age-related Macular Degeneration Diagnosis
AMD rarely causes symptoms in its early stages, annual eye examinations are key to detecting the disease and starting treatments when they are most effective. During an eye exam, the eye healthcare provider checks for changes to the retina and macula. Patients may get one or more of these tests:
&nbsp;
Visual field test: An Amsler grid has a grid of straight lines with a large dot in the center. The healthcare provider asks to identify lines or sections on the grid that look blurry, wavy, or broken. A lot of distortion may indicate that patient have AMD or the disease is worsening. Patient can use this visual field test at home to monitor vision.
&nbsp;
Dilated eye exam: Eye drops dilate, or widen, patient pupils. Once patient&rsquo;s eyes are dilated, healthcare provider uses a special lens to look inside patient&rsquo;s eyes.
&nbsp;
Fluorescein angiography (FA): Healthcare provider injects a yellow dye called fluorescein into a vein in patient&rsquo;s arm. A special camera tracks the dye as it travels through blood vessels in the eye. The photos can reveal any leakage under the macula.
&nbsp;
Optical coherence tomography (OCT): This imaging machine takes detailed images of the back of the eye, including the retina and macula. Optical coherence tomography isn&rsquo;t invasive or painful. Patient simply look into a lens while the machine takes pictures.
&nbsp;
Optical coherence tomography angiography (OCTA): This diagnostic tool uses laser light reflection (instead of fluorescein dye) and the OCT scanning device. It takes just a few moments and produces 3D images of blood flow through the eye.
Continued in the report&hellip;..
<h2>Age-related Macular Degeneration Epidemiology Perspective by DelveInsight</h2>
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases AMD, diagnosed prevalent cases of AMD, type-specific cases of AMD (Dry AMD, and Wet AMD), total age-specific cases of AMD (Dry AMD and Wet AMD), total diagnosed dry AMD cases by stages, and total geographic atrophy cases by visual impairment in the scenario of Age-related Macular Degeneration in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2021 to 2034.
<h2>Age-related Macular Degeneration Detailed Epidemiology Segmentation</h2>
<ul>
<li>In the year 2021, the total prevalent cases of AMD were approximately 51,743,361 in the 7MM, which might increase at a CAGR of 1.6% by 2034.</li>
<li>The US accounted for approximately 17,282,569 prevalent cases of AMD in the year 2021.</li>
<li>In EU-5 countries the highest number of prevalent cases of AMD was observed in Germany with 7,850,793 cases in the year 2021, followed by France.</li>
<li>Among the 7MM, Japan accounted for approximately 21% prevalent cases of AMD in the year 2021.</li>
<li>In the year 2021, the total diagnosed cases of AMD were approximately 38,807,521 cases in the 7MM. The highest number of cases were diagnosed in the US.</li>
<li>In the 7MM, the analysis of type-specific cases of AMD revealed that there were approximately 3,880,752 and 34,926,768 cases of Wet-AMD and Dry-AMD, respectively in the year 2021. These cases are expected to increase by multiple number of folds by 2034.</li>
<li>In the epidemiology model, the total age-specific cases of AMD (Dry-AMD, and Wet-AMD), are divided into age group 50-59 years, 60&ndash;69 years, 70&ndash;79 years, and &ge;80 years respectively. As per the estimates by DelveInsight, the total age-specific cases of AMD are expected to increase during the forecasted period of 2022&ndash;2034.</li>
<li>In the US, the total diagnosed cases of dry AMD by age distribution were 2,175,435; 3,380,209; 3,495,783; and 2,614,307 cases for the age group 50&ndash;59 years, 60&ndash;69 years, 70&ndash;79 years, and &ge; 80 years in 2021.</li>
<li>In the US, the total diagnosed cases of dry AMD by stages were approximately 10,499,160 cases for early and intermediate dry AMD and 1,166,573 cases for advanced (geographic atrophy associated with dry AMD) in 2021. As per the analysis, stage-wise cases are also expected to by 2034.</li>
<li>In the US, the total geographic atrophy cases by visual impairment were 349,972; 583,287; and 233,315 cases for mild, moderate to severe, and patients going for surgery or having legal blindness, respectively, in 2021.</li>
</ul>
<h2>Scope of the Report</h2>
<ul>
<li>The report covers the descriptive overview of Age-related Macular Degeneration, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.</li>
<li>The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.</li>
<li>The report assesses the disease risk and burden of Age-related Macular Degeneration.</li>
<li>The report helps to recognize the growth opportunities in the 7MM concerning the patient population.</li>
<li>The report provides the segmentation of the disease epidemiology for 7MM, total prevalent cases AMD, diagnosed prevalent cases of AMD, type-specific cases of AMD (Dry AMD, and Wet AMD), total age-specific cases of AMD (Dry AMD and Wet AMD), total diagnosed dry AMD cases by stages, and total geographic atrophy cases by visual impairment.</li>
</ul>
<h2>Report Highlights</h2>
<ul>
<li>10-year forecast of Age-related Macular Degeneration</li>
<li>The 7MM Coverage</li>
<li>Total Prevalent Cases of Age-related Macular Degeneration</li>
<li>Diagnosed Prevalent Cases of Age-related Macular Degeneration</li>
<li>Type-specific Cases of AMD (Dry-AMD, and Wet-AMD)</li>
<li>Total Age-specific Cases of AMD (Dry-AMD, and Wet-AMD)</li>
<li>Total Diagnosed dry AMD cases by stages</li>
<li>Total Geographic Atrophy Cases by Visual Impairment</li>
</ul>
<h2>Key Questions Answered</h2>
<ul>
<li>What are the disease risk and burdens of Age-related Macular Degeneration?</li>
<li>What is the historical Age-related Macular Degeneration patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?</li>
<li>What would be the forecasted patient pool of Age-related Macular Degeneration at the 7MM level?</li>
<li>What will be the growth opportunities across the 7MM concerning the patient population about Age-related Macular Degeneration?</li>
<li>Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Age-related Macular Degeneration during the forecast period (2025-2034)?</li>
<li>At what CAGR the population is expected to grow across the 7MM during the forecast period (2025-2034)?</li>
</ul>
<h2>Reasons to buy</h2>
The Age-related Macular Degeneration report will allow the user to -
<ul>
<li>Develop business strategies by understanding the trends shaping and driving the 7MM Age-related Macular Degeneration epidemiology forecast.</li>
<li>The Age-related Macular Degeneration epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.</li>
<li>The Age-related Macular Degeneration epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.</li>
</ul>
<h2>Key Assessments</h2>
<ul>
<li>Patient Segmentation</li>
<li>Disease Risk and Burden</li>
<li>Risk of disease by the segmentation</li>
<li>Factors driving growth in a specific patient population</li>
</ul>

1. Key Insights
2. Report Introduction
3. Age-related Macular Degeneration Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of Age-related Macular Degeneration in 2021
3.2. Patient Share (%) Distribution of Age-related Macular Degeneration in 2034
4. Key Events
5. Executive Summary
5.1. Wet AMD
5.2. Dry AMD
6. Disease Background and Overview
6.1. Introduction
6.1.1. Classification and Clinical Manifestation
6.1.2. Signs and Symptoms of AMD
6.1.3. Risk Factors
6.1.4. Pathophysiology of AMD
6.2. Diagnosis
6.3. Diagnostic Guidelines
6.3.1. NICE Guidelines
6.3.2. American Academy of Ophthalmology
6.3.3. Harvard Ophthalmology
6.3.4. European Society of Retina Specialists (EURETINA)
7. Patient Journey
8. Key Opinion Leaders&rsquo; Views
9. Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale: 7MM
9.2.1. Prevalent Cases of AMD
9.2.2. Diagnosed Prevalent Cases of AMD
9.2.3. Type-specific cases of AMD
9.2.4. Age-specific Cases of AMD
9.2.5. Dry AMD Cases by Stage
9.2.6. Geographic Atrophy (GA) Cases by Visual Impairment (%)
9.3. Total Prevalent Cases of AMD in the 7MM
9.4. Type-specific Diagnosed Prevalent Cases of AMD in the 7MM
9.5. The United States
9.5.1. Total Prevalent Cases of AMD
9.5.2. Total Diagnosed Cases of AMD
9.5.3. Type-specific Cases of AMD
9.5.4. Total Age-specific Cases of AMD
9.5.5. Total Diagnosed Dry AMD Cases by Stages in the US
9.5.6. Total Geographic Atrophy Cases by Visual Impairment in the US
9.6. EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
9.6.1. Germany
9.6.1.1. Total Prevalent Cases of AMD
9.6.1.2. Total Diagnosed Cases of AMD
9.6.1.3. Type-specific Cases of AMD
9.6.1.4. Total Age-specific Cases of AMD
9.6.1.5. Total Diagnosed Dry AMD Cases by Stage
9.6.1.6. Total Geographic Atrophy Cases by Visual Impairment
9.6.2. France
9.6.2.1. Total Prevalent Cases of AMD
9.6.2.2. Total Diagnosed Cases of AMD
9.6.2.3. Type-specific Cases of AMD
9.6.2.4. Total Age-specific Cases of AMD
9.6.2.5. Total Diagnosed Dry AMD Cases by Stage
9.6.2.6. Total Geographic Atrophy Cases by Visual Impairment
9.6.3. Italy
9.6.3.1. Total Prevalent Cases of AMD
9.6.3.2. Total Diagnosed Cases of AMD
9.6.3.3. Type-specific Cases of AMD
9.6.3.4. Total Age-specific Cases of AMD
9.6.3.5. Total Diagnosed Dry AMD Cases by Stage
9.6.3.6. Total Geographic Atrophy Cases by Visual Impairment
9.6.4. Spain
9.6.4.1. Total Prevalent Cases of AMD
9.6.4.2. Total Diagnosed Cases of AMD
9.6.4.3. Type-specific Cases of AMD
9.6.4.4. Total Age-specific Cases of AMD
9.6.4.5. Total Diagnosed Dry AMD Cases by Stage
9.6.4.6. Total Geographic Atrophy Cases by Visual Impairment
9.6.5. The United Kingdom
9.6.5.1. Total Prevalent Cases of AMD
9.6.5.2. Total Diagnosed Cases of AMD
9.6.5.3. Type-specific Cases of AMD
9.6.5.4. Total Age-specific Cases of AMD
9.6.5.5. Total Diagnosed Dry AMD Cases by Stage
9.6.5.6. Total Geographic Atrophy Cases by Visual Impairment
9.7. Japan
9.7.1. Total Prevalent Cases of AMD
9.7.2. Total Diagnosed Cases of AMD
9.7.3. Type-specific Cases of AMD
9.7.4. Total Age-specific Cases of Wet AMD
9.7.5. Total Diagnosed Dry AMD Cases by Stages in Japan
9.7.6. Total Geographic Atrophy Cases by Visual Impairment Japan
10. Appendix
10.1. Bibliography
10.2. Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight

DelveInsight's "Age-related Macular Degeneration (AMD) - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Age-related Macular Degeneration (AMD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Age-related Macular Degeneration (AMD) - Epidemiology Forecast - 2034

DelveInsight's Age-related Macular Degeneration (AMD) - Epidemiology Forecast 2034 report delivers an in-depth understanding..